ClinicalTrials.gg
RecruitingNCT06901869ActivPARKUpdated Apr 4, 2025

Physical Activity in Persons With Parkinson's Disease

An observational study in Parkinson Disease and Physical Inactivity, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Karolinska Institutet · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Parkinson Disease by Karolinska Institutet — 3 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · Karolinska Institutet.

Started
2025
the only one that year
Observational
4 of 10
2 open now
Registered
8th of 10
by date

Among the 10 studies in Parkinson Disease by Karolinska Institutet, this one is the only one that started in 2025, is one of 4 observational ones, and was the 8th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 10 studies in Parkinson Disease by Karolinska Institutet are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Parkinson Disease by Karolinska Institutet, or all of them as a file.
02

Study summary

Parkinson's disease (PD) is a leading neurodegenerative health condition in Sweden and a public health concern. Although no cure exists, functional independence and participation in society remain top priorities, and can be achieved through targeted physical activity (PA) interventions. To date, few longitudinal cohort studies have been conducted, using PA as main outcome in therapy research, partly due to the complex nature of predicting and controlling this phenomenon. To help address this knowledge gap, the overall purpose of the future long-term (ActivPARK) study is to enhance knowledge of the evolution of PA behavior, and how it is influenced beyond the disease characteristics using a broad explanatory model, in persons with PD from a diversity of settings in Sweden with the aim of prescribing tailored and personalized interventions to enhance functioning, health, and wellbeing throughout the disease progression and recommend potential health care pathway modifications.

The investigators have just established an expert group, comprising researchers, healthcare professionals, and PD organisations (including persons with PD) and reached consensus on essential priority clinical therapy research questions on PA and methodological considerations. The next phase entails performing a multicentre feasibility/pilot study, further developing and refining the assessment battery and research questions linked to the improved explanatory model for PA and methodology, to inform the definite larger clinical cohort study.

03

Conditions studied

  • Parkinson Disease
  • Physical Inactivity
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Parkinson's disease with mild to severe severity (Hoehn \& Yahr 1-4) of all ages

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Parkinson's disease
  • Mild to severe disease severity ( Hoehn \& Yahr 1-4).

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • People with Parkinson's disease

    No intervention

06

What researchers measure

Primary outcomes

  1. Feasibility of the assessment battery - length of the clinical examination and questionnaires

    The pilot/feasibility study aims to evaluate feasibility of the assessment battery measured the time it takes to complete the examination and questionnaires.

    Time frame: Baseline

  2. Feasibility of the assessment battery - perception of the clinical examination

    Feasibility of the assessment battery will also be evaluated through semi-structured questions regarding fatique, concentration, pain/discomfort to the participants after the clinical examination.

    Time frame: Baseline

  3. Feasibility of the assessment battery -Compliance to questionnaires sent via REDCap

    Compliance will be measured with percentages of completed questionnaires in REDCap.

    Time frame: Baselline

  4. Feasibility of the assessment battery - Suitability of the primary outcome

    Suitability of the accelerometers in the home environment as the primary outcome for the targeted patient group will be assessed by the percentage of participants that are able to wear the accelerometer for at least 4 days days and render valid data.

    Time frame: Baseline

  5. Physical activity levels

    The ActiGraph accelerometer (GT3X+, ActiGraph, Pensacola, FL, US) will be used to measure absolute and relative time spent in sedentary behavior, low intensity physical activity (LIPA) and moderate to vigorous intensity physical activity (MVPA), by total time in bouts.

    Time frame: Baseline

Secondary outcomes

  1. Physical activity - self rated

    Frändin Grimby scale, ranging from 1 to 6, higher score=better.

    Time frame: Baseline

  2. Disease severity, Parkinson symptoms

    Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS- UPDRS) parts 1 to 4. Higher scores = worse/more symptoms

    Time frame: Baseline

  3. Gait

    Gait speed in m/s measured with the 10 meter walking test or through gait analysis.

    Time frame: Baseline

  4. Balance performance

    Assessed with the Mini-BESTest. Mini-Balance Evaluation Systems Test a rating scale for dynamic balance incorporating 14 different balance and gait items that were assessed by a physical therapist on a scale from 0-2. Maximum points 28. 0-28 points with higher scores indicating better balance control

    Time frame: Baseline

  5. Anxiety and depression

    Assessed with Hospital Anxiety and Depression Scale (HADS), 0-24 on the depression and anxiety part respectively. Lower score=better

    Time frame: Baseline

  6. Cognitive performance

    Assessed with the Montreal Cognitive Assessment (MoCA), 0-25, higher score = better

    Time frame: Baseline and 3 year follow-up

  7. Self assessed cognitive function

    Assessed with Executive function questionnaire (DEX), 20 items scored 1 to 4, max 80, more scores= worse.

    Time frame: Baseline

  8. Non-Motor Symptoms

    Non-Motor Symptoms Questionnaire (NMSQ), 30 questions with yes/no answer. More yes answers = more non-motor symptoms

    Time frame: Baseline

  9. Walking ability- self assessed

    WALK-12G questionnaire, 0 and 42 points, with higher scores reflecting greater perceived walking difficulties (higher=worse)

    Time frame: Baseline

  10. Freezing of gait - self-assessed

    Freezing of gait questionnaire (FOGQsa), 6 questions/items, scored 1 to 5 (higher=worse)

    Time frame: Baseline

  11. Balance confidence

    Activities specific balance confidence (ABC scale), 16 items which is scored 1 to 10 and then divided by 16. 0-100%, higher % = better

    Time frame: Baseline

  12. Motivation

    Behavioural Regulation in Exercise Questionnaire (BREQ 4), 28 items score 1 to 7 and divided into subcomponents: Amotivation, External regulation, Introjected avoidance, Introjected approach, Identified regulation, Integrated regulation, Intrinsic regulation

    Time frame: Baseline

  13. Fatigue

    Parkinson's Fatigue Scale (PFS-16), 16 items scored 1 to 5 from strongly disagree to strongly agree . more points/score= worse.

    Time frame: Baseline

  14. Disability

    World health organization (WHO) disability assessment schedule (Whodas 2.0), 12 self-assessed questions (12 to 60) more points=worse

    Time frame: Baseline

  15. Self-efficacy

    Self-efficacy of exercise/PA (ESES), 10 questions, scored 1-4. higher=better

    Time frame: Baseline

  16. Sleep

    Scales for Outcomes in Parkinson's disease - Sleep (SCOPA-SLEEP), 4 parts, A-2 questions, B-5 questions , C-1 question and D- 6 questions. Higher= worse

    Time frame: Baseline

  17. Self rated pain

    Assessed with visual analog scale, VAS from 0 to 100

    Time frame: Baseline

  18. Health related quality of life

    Parkinson's Disease Questionnaire (PDQ39). The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people with Parkinson's experience difficulties across 8 dimensions of daily living (mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communications and bodily discomfort). The sum score is as a percentage score ranging between 0 and 100. Higher is better

    Time frame: Baseline

  19. Wellbeing

    The WHO- Five Well-Being Index (WHO-5), 5 questions ranging from 0 to 5, 0-25, higher=better

    Time frame: Baseline

  20. Nutrition

    Mini Nutritional Assessment, max 14. higher = better

    Time frame: Baseline

Other outcomes

  1. Working och long-term memory

    Rey-Auditory Verbal Learning Test (RAVLT), higher= better

    Time frame: Baseline

  2. Parkinson related pain

    Assessed with the Kings Parkinsons Pain Scale (KPPS), max 168, higher= more pain

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The datasets generated during and/or analysed during the current study are not publicly available due to Swedish and EU personal data legislation but are available from the principal investigator on reasonable request. Any sharing of data will be regulated via a data transfer and user agreement with the recipient, provided that the recipient has an approved ethics application.

Supporting information: Statistical analysis plan

Time frame: The investigators plan to share this when applicable on OSF or similar

Access criteria: The datasets generated during and/or analysed during the current study are not publicly available due to Swedish and EU personal data legislation but are available from the principal investigator on reasonable request. Any sharing of data will be regulated via a data transfer and user agreement with the recipient.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 21 months is below that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Mar 30, 2025
StartActual
Mar 25, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06901869
Responsible party
Erika Franzén (Professor, Karolinska Institutet) — Principal investigator
First posted
Mar 30, 2025
Start date
Mar 25, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 4, 2025

Study contacts

Compliance Office Karolinska Insitutet
Contact
compliance@ki.se
+46852480000
Erika Franzén
Contact
erika.franzen@ki.se
+46852488878
Erika Franzén
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion